Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the hip, knee, or spine for 1 year or longer, confirmed by radiographic evidence within the last 2 years.~* Good pain control while on a stable dose of an opioid analgesic for osteoarthritis.~Exclusion Criteria:~* Not currently taking and tolerating opioids.~* Taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment.~* Requiring frequent analgesic therapy for chronic condition(s), in addition to osteoarthritis.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BTDS 5 (Type: ACTIVE_COMPARATOR): Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
- BTDS 20 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
- Oxycodone Immediate-Release (Oxy IR) 40 mg (Type: EXPERIMENTAL): Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).